CU24075B1 - Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular. - Google Patents

Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.

Info

Publication number
CU24075B1
CU24075B1 CU2011000167A CU20110167A CU24075B1 CU 24075 B1 CU24075 B1 CU 24075B1 CU 2011000167 A CU2011000167 A CU 2011000167A CU 20110167 A CU20110167 A CU 20110167A CU 24075 B1 CU24075 B1 CU 24075B1
Authority
CU
Cuba
Prior art keywords
activating peptide
pituitary
pacap
adenylate
cycling
Prior art date
Application number
CU2011000167A
Other languages
English (en)
Other versions
CU20110167A7 (es
Inventor
González Juana María Lugo
González Yamila Carpio
García Mario Pablo Estrada
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CU2011000167A priority Critical patent/CU24075B1/es
Priority to BR112014004620-4A priority patent/BR112014004620B1/pt
Priority to RU2014111465/15A priority patent/RU2580294C2/ru
Priority to AU2012303887A priority patent/AU2012303887B2/en
Priority to PCT/CU2012/000004 priority patent/WO2013029570A1/es
Priority to JP2014526385A priority patent/JP6077541B2/ja
Priority to PT127751238T priority patent/PT2749291T/pt
Priority to CN201280041829.5A priority patent/CN103874510A/zh
Priority to CA2844898A priority patent/CA2844898C/en
Priority to MYPI2014700419A priority patent/MY191697A/en
Priority to NO12775123A priority patent/NO2749291T3/no
Priority to EP12775123.8A priority patent/EP2749291B1/en
Priority to SG11201400215SA priority patent/SG11201400215SA/en
Priority to MX2014002214A priority patent/MX351725B/es
Priority to ES12775123.8T priority patent/ES2648337T3/es
Priority to US14/238,377 priority patent/US9549977B2/en
Priority to KR1020147006186A priority patent/KR101857705B1/ko
Publication of CU20110167A7 publication Critical patent/CU20110167A7/es
Priority to CL2014000386A priority patent/CL2014000386A1/es
Priority to ZA2014/01271A priority patent/ZA201401271B/en
Publication of CU24075B1 publication Critical patent/CU24075B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con composiciones vacunales que comprenden el péptido activador de la adenilato ciclasa de pituitaria (PACAP) como adyuvante molecular para vacunas. Dichas vacunas pueden emplearse en la protección contra agentes infecciosos, tales como virus, bacterias y ectoparásitos que afectan a los mamíferos, las aves y a los organismos acuáticos. El PACAP, combinado con un antígeno particular, demuestra su efectividad como adyuvante al aumentar la respuesta inmunológica del huésped contra dicho antígeno. Este tipo de respuesta puede observarse cuando las composiciones o combinaciones vacunales que comprenden PACAP se administran por vía oral, inyección, o por baños de inmersión en el caso de los organismos acuáticos.
CU2011000167A 2011-08-26 2011-08-26 Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular. CU24075B1 (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CU2011000167A CU24075B1 (es) 2011-08-26 2011-08-26 Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
MYPI2014700419A MY191697A (en) 2011-08-26 2012-08-24 Use of the pacap as a molecular adjuvant for vaccines
NO12775123A NO2749291T3 (es) 2011-08-26 2012-08-24
AU2012303887A AU2012303887B2 (en) 2011-08-26 2012-08-24 Use of the PACAP as a molecular adjuvant for vaccines
PCT/CU2012/000004 WO2013029570A1 (es) 2011-08-26 2012-08-24 Uso del pacap como adyuvante molecular para vacunas
JP2014526385A JP6077541B2 (ja) 2011-08-26 2012-08-24 ワクチンのための分子アジュバントとしてのｐａｃａｐの使用
PT127751238T PT2749291T (pt) 2011-08-26 2012-08-24 Utilização de pacap como um adjuvante molecular para vacinas
CN201280041829.5A CN103874510A (zh) 2011-08-26 2012-08-24 Pacap作为用于疫苗的分子佐剂的用途
CA2844898A CA2844898C (en) 2011-08-26 2012-08-24 Use of the pacap as a molecular adjuvant for vaccines
BR112014004620-4A BR112014004620B1 (pt) 2011-08-26 2012-08-24 uso do ‘peptídeo ativador da adenilato ciclase de pituitária’, composição de vacina e combinação de vacina
RU2014111465/15A RU2580294C2 (ru) 2011-08-26 2012-08-24 Применение расар в качестве молекулярного адъюванта для вакцин
EP12775123.8A EP2749291B1 (en) 2011-08-26 2012-08-24 Use of pacap as a molecular adjuvant for vaccines
SG11201400215SA SG11201400215SA (en) 2011-08-26 2012-08-24 Use of the pacap as a molecular adjuvant for vaccines
MX2014002214A MX351725B (es) 2011-08-26 2012-08-24 Uso del peptido activador de la adelinato ciclasa de pituitaria como adyuvante molecular para vacunas.
ES12775123.8T ES2648337T3 (es) 2011-08-26 2012-08-24 Uso del PACAP como adyuvante molecular para vacunas
US14/238,377 US9549977B2 (en) 2011-08-26 2012-08-24 Use of the PACAP as a molecular adjuvant for vaccines
KR1020147006186A KR101857705B1 (ko) 2011-08-26 2012-08-24 백신용 분자 아쥬반트로서 뇌하수체 아데닐산 고리화효소 활성화 펩타이드의 용도
CL2014000386A CL2014000386A1 (es) 2011-08-26 2014-02-14 Combinacion vacunal que comprende el peptido activador de adenilato ciclasa de pituitaria (pacap) y al menos un antigeno vacunal; composicion vacunal que la comprende; y metodo para incrementar la respuesta inmune contra el antigeno vacunal por parte del pacap que sirve como adyuvante molecular.
ZA2014/01271A ZA201401271B (en) 2011-08-26 2014-02-19 Use of the pacap as a molecular adjuvant for vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2011000167A CU24075B1 (es) 2011-08-26 2011-08-26 Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.

Publications (2)

Publication Number Publication Date
CU20110167A7 CU20110167A7 (es) 2013-06-28
CU24075B1 true CU24075B1 (es) 2015-01-29

Family

ID=47046313

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000167A CU24075B1 (es) 2011-08-26 2011-08-26 Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.

Country Status (19)

Country Link
US (1) US9549977B2 (es)
EP (1) EP2749291B1 (es)
JP (1) JP6077541B2 (es)
KR (1) KR101857705B1 (es)
CN (1) CN103874510A (es)
AU (1) AU2012303887B2 (es)
BR (1) BR112014004620B1 (es)
CA (1) CA2844898C (es)
CL (1) CL2014000386A1 (es)
CU (1) CU24075B1 (es)
ES (1) ES2648337T3 (es)
MX (1) MX351725B (es)
MY (1) MY191697A (es)
NO (1) NO2749291T3 (es)
PT (1) PT2749291T (es)
RU (1) RU2580294C2 (es)
SG (1) SG11201400215SA (es)
WO (1) WO2013029570A1 (es)
ZA (1) ZA201401271B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190060057A (ko) 2017-11-24 2019-06-03 유병희 웰빙 무드등
EP3970796A4 (en) * 2019-05-14 2022-12-21 Senju Pharmaceutical Co., Ltd. COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS CONTAINING A PACAP-LIKE PEPTIDE OR A STABILIZED PACAP-LIKE PEPTIDE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE65568B1 (en) * 1990-10-22 1995-11-01 Unilever Plc Vaccine compositions for fish
RU2269354C2 (ru) * 1999-09-28 2006-02-10 Байер Корпорейшн Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
CU23557A1 (es) * 2005-11-22 2010-07-20 Ct Ingenieria Genetica Biotech Neuropéptidos para el cultivo de organismos acuáticos
WO2011054001A2 (en) * 2009-11-02 2011-05-05 The Administrators Of The Tulane Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN103255089B (zh) * 2013-05-03 2015-08-05 中国水产科学研究院黄海水产研究所 一株强毒迟缓爱德华氏菌疫苗株及其应用

Also Published As

Publication number Publication date
CU20110167A7 (es) 2013-06-28
CA2844898A1 (en) 2013-03-07
CA2844898C (en) 2021-06-22
EP2749291B1 (en) 2017-10-18
AU2012303887A1 (en) 2014-03-06
KR20140064847A (ko) 2014-05-28
WO2013029570A1 (es) 2013-03-07
MY191697A (en) 2022-07-07
EP2749291A1 (en) 2014-07-02
BR112014004620B1 (pt) 2019-10-29
JP6077541B2 (ja) 2017-02-08
JP2014524450A (ja) 2014-09-22
US9549977B2 (en) 2017-01-24
PT2749291T (pt) 2017-11-24
MX351725B (es) 2017-10-25
ZA201401271B (en) 2015-04-29
SG11201400215SA (en) 2014-09-26
AU2012303887B2 (en) 2017-06-22
RU2014111465A (ru) 2015-10-10
MX2014002214A (es) 2014-04-30
KR101857705B1 (ko) 2018-06-20
BR112014004620A2 (pt) 2017-03-21
ES2648337T3 (es) 2018-01-02
NO2749291T3 (es) 2018-03-17
RU2580294C2 (ru) 2016-04-10
US20140294889A1 (en) 2014-10-02
CL2014000386A1 (es) 2014-07-11
CN103874510A (zh) 2014-06-18

Similar Documents

Publication Publication Date Title
ECSP14013315A (es) Inhibidores de aplicación viral
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
ECSP13012622A (es) Compuestos antivirales
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
ECSP14005678A (es) Composiciones y métodos para tratar el virus de la hepatitis c
CO2017010162A2 (es) Nucleótidos de purina ß-d-2'-desoxi-2'-α-fluoro-2'-ß-c-sustituidos-2-modificados-n6-sustituidos para el tratamiento del virus de la hepatitis c
UY34066A (es) Inhibidores del virus de la hepatitis c
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
AR088580A1 (es) Metodos y composiciones para tratar el virus de la hepatitis c
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
BR112014015582A2 (pt) compostos antivirais
CU20110167A7 (es) Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
AR097029A1 (es) Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CU20160161A7 (es) Composicion vacunal que comprende un péptido secretagogo de la hormona de crecimiento como adyuvante vacunal
CL2013001561A1 (es) Composicion que comprende al polipeptido activador de la adenilato ciclasa de pituitaria (pacap); combinacion veterinaria que comprende al pacap y una molecula antiviral; y uso del pacap para el tratamiento de enfermedades infecciosas causadas por virus en organismos acuaticos.
ECSP21087299A (es) Composiciones y métodos para tratar el virus de la hepatitis c
NI201400025A (es) Inhibidores de aplicación viral
AR082057A1 (es) Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (i)

Legal Events

Date Code Title Description
FG Grant of patent